Zusammenfassung
Hintergrund
Die Inzidenz des hepatozellulären Karzinoms (HCC) ist in den letzten Jahren weiter gestiegen. Dies wird auf alkoholische Lebererkrankungen, das metabolische Syndrom sowie die steigende Inzidenz der Virushepatitis B und C zurückgeführt.
Fragestellung
Auswertung der Epidemiologie des hepatozellulären Karzinoms (HCC), Darstellung und Diskussion der Risikofaktoren zur Entwicklung eines hepatozellulären Karzinoms (HCC).
Material und Methoden
Literaturrecherche, Auswertung der Statistiken der Weltgesundheitsorganisation (WHO), Diskussion aktueller Grundlagenarbeiten und Expertenempfehlungen.
Ergebnisse
Das HCC stellt bereits das fünfthäufigste Malignom bei Männern und das neunthäufigste Malignom bei Frauen mit weiter steigender Inzidenz dar. Für das Auftreten des hepatozellulären Karzinoms und bzgl. der Risikofaktoren zeigen sich große regionale Unterschiede, der bedeutendste Faktor ist die unterschiedliche Prävalenz der chronischen Virushepatitis B.
Schlussfolgerung
Das HCC stellt ein bedeutendes medizinisches Problem dar. Primärpräventive Maßnahmen sowie geeignete Screeningalgorithmen gewinnen zunehmend an Bedeutung.
Abstract
Background
The incidence of hepatocellular carcinoma (HCC) has increased over the past decades as a result of alcoholic liver disease, the metabolic syndrome and the increasing incidence of viral hepatitis B and C.
Objectives
An evaluation of the epidemiology of HCC, presentation and discussion of the risk factors for the development of HCC.
Material and methods
This study was based on a literature review, analysis of the statistics of the World Health Organization (WHO), discussion of current basic research and expert recommendations.
Results
The results show that HCC already represents the fifth most common malignancy in men and the ninth most common malignancy in women, and the incidence is still rising. The pronounced regional differences in prevalence and underlying risk factors are mainly, but not exclusively, due to the prevalence of chronic viral hepatitis B.
Conclusion
Hepatocellular carcinoma is a major medical problem. Primary prevention measures and suitable screening algorithms are gaining more and more importance.
Literatur
Ascha MS, Hanouneh IA, Lopez R et al (2010) The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51(6):1972–1978
Bressac B, Kew M, Wands J, Ozturk M (1991) Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350:429–431
Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022
Chen CJ, Yang HI, Su J et al (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295(1):65–73
Davila JA, Morgan RO, Shaib Y et al (2005) Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 54(4):533–539
El-Serag HB, Davilla JA, Petersen NJ, McGlynn KA (2003) The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139(10):817–823
El-Serag HB (2011) Hepatocellular carcinoma. N Engl J Clin 61:69–90
Ertle J, Dechêne A, Sowa JP et al (2011) Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 128(10):2436–2443
Fattovich G, Stroffolini T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127(5):S35–S50
Harada K, Hirohara J, Ueno Y et al (2013) Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: national data from Japan. Hepatology 57(5):1942–1949
Hassan MM, Hwang LY, Hatten CJ et al (2002) Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 36(5):1206–1213
Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90
Nault JC, Bioulac-Sage P, Zucman-Rossi J (2013) Hepatocellular benign tumors – from molecular classification to personalized clinical care. Gastroenterology 144:888–902
Perz JF, Armstrong GL, Farrington LA et al (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45(4):529–538
Ratziu V, Bellentani S, Cortez Pinto H et al (2010) A position statement on NAFLD/NASH based on the ASL 2009 special conference. J Hepatol 53(2):372–384
Starley BQ, Calcagno CJ, Harrison SA (2010) Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51(5):1820–1832
Tsukuma H, Hyama T, Tanaka S et al (1993) Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328:1797–1801
Ueno Y, Nagata S, Tsutsumi T et al (1996) Detection of microcystins, a blue-green algal hepatotoxin, in drinking water sampled in Haimen and Fusui, endemic areas of primary liver cancer in China, by highly sensitive immunoassay. Carcinogenesis 17:1317–1321
Weltgesundheitsorganisation WHO, International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr
Welzel TM, Graubard BI, Zeuzem S et al (2011) Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 54(2):463–471
Yoshimoto S, Loo TM, Atarashi K et al (2013) Obesity-induced gut microbial metabolite promotes liver cancer through senescense secretome. Nature 499:97–101
Yuen MF, Tanaka Y, Fong DY et al (2009) Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 50:80–88
Einhaltung ethischer Richtlinien
Interessenkonflikt. M.M. Dollinger weist auf folgende Beziehungen hin: grant support by Bayer, Roche, Novartis. M. Güthle gibt an, dass kein Interessenskonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Güthle, M., Dollinger, M. Epidemiologie und Risikofaktoren des hepatozellulären Karzinoms. Radiologe 54, 654–659 (2014). https://doi.org/10.1007/s00117-014-2650-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00117-014-2650-6